What are the well‑established strategies to prevent decompensation in an adult with compensated Child‑Pugh A cirrhosis?

Preventing Decompensation in Compensated Child-Pugh A Cirrhosis

All patients with compensated Child-Pugh A cirrhosis and clinically significant portal hypertension (CSPH) should be treated with non-selective beta-blockers (NSBBs) or carvedilol to prevent decompensation, including ascites, variceal bleeding, and hepatic encephalopathy. 1

Identifying Patients Who Need Treatment

Screen for CSPH Using Non-Invasive Tests

The critical first step is identifying which compensated cirrhosis patients have CSPH, as this defines the threshold (portal pressure ≥10 mmHg) from which decompensating events may occur 2:

• Liver stiffness measurement (LSM) >20-25 kPa or platelet count <150 G/L indicates probable or confirmed CSPH 1
• LSM >25 kPa has high likelihood of CSPH; NSBBs/carvedilol may be started without endoscopy 1
• LSM 20-25 kPa: Perform endoscopy if not already on NSBBs/carvedilol, and start treatment if varices present 1
• LSM <12 kPa with platelets >150 G/L excludes CSPH; these patients can be discharged from CSPH surveillance 1

Primary Prevention Strategy: Beta-Blockers

Evidence Base

The paradigm has shifted from treating only high-risk varices to treating all patients with CSPH to prevent any decompensation event 1. The PREDESCI study demonstrated that beta-blockers prevent not only variceal bleeding but also non-bleeding decompensation events, particularly ascites (the most common first decompensating event) 1, 3.

Who Benefits

• Patients with any size varices and CSPH should receive NSBBs/carvedilol 1
• Even patients with small varices benefit, as treatment prevents ascites development and variceal growth 3, 4
• Benefit persists even after etiological treatment (e.g., HCV cure): NSBBs reduced decompensation from 44% to 16% in patients with enduring CSPH after viral cure 4

Mechanism

Beta-blockers are only effective when hyperdynamic circulation exists (HVPG >10 mmHg), which is why CSPH identification is crucial 1. They reduce portal pressure and decrease bacterial translocation, thereby lowering infection rates 4.

Treat the Underlying Etiology

Viral Hepatitis

• HCV cure with direct-acting antivirals can lead to regression of CSPH and even allow discontinuation of beta-blockers if post-treatment LSM decreases to <12 kPa with platelets >150 G/L 1
• HBV suppression with antivirals improves outcomes in compensated cirrhosis 1

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

• Weight reduction of 7-10% through lifestyle modification is the cornerstone 1
• GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) or co-agonists (tirzepatide) for patients with type 2 diabetes 1
• SGLT2 inhibitors (empagliflozin, dapagliflozin) can be used in Child-Pugh A cirrhosis 1
• Resmetirom if locally approved for F2/F3 fibrosis 1
• Statins should be continued according to cardiovascular risk guidelines; they are safe in compensated cirrhosis and may have beneficial effects on portal hypertension 1, 5

Alcohol-Related Liver Disease

• Complete alcohol abstinence is essential, as even moderate consumption worsens portal hypertension and can precipitate decompensation 1
• Portal pressure deteriorates within 15 minutes of alcohol consumption (0.5 g/kg) in alcoholic cirrhosis 1

Nutritional and Metabolic Management

Protein and Calorie Intake

• Supply at least 35 kcal/kg body weight/day 1
• Protein intake of 1.2-1.5 g/kg body weight/day with emphasis on maintaining muscle mass 1
• Late evening snack (between 7-10 PM) to prevent prolonged fasting 6
• Small frequent meals rather than three large meals 6

Diabetes Management

• Screen for diabetes given high prevalence (30%) in cirrhosis 1
• Metformin can be used if GFR >30 mL/min in compensated cirrhosis 1
• Avoid sulfonylureas due to hypoglycemia risk 1
• GLP-1 receptor agonists and SGLT2 inhibitors are safe in Child-Pugh A cirrhosis 1

Coffee Consumption

• 2 or more cups of coffee daily should be encouraged in stable outpatients 6

Prevent Bacterial Infections

Bacterial infections are independent predictors of decompensation and increase mortality fourfold 1:

• NSBBs reduce bacterial infection rates (HR 0.36) by decreasing bacterial translocation 4
• Maintain high index of suspicion for infections, as they can precipitate acute-on-chronic liver failure 1

Surveillance and Monitoring

Hepatocellular Carcinoma Screening

• Ultrasound with or without AFP every 6 months regardless of etiology 1
• Annual HCC incidence is 1-7% in compensated cirrhosis 1

Endoscopic Surveillance

• Perform endoscopy based on LSM thresholds as outlined above 1
• Patients already on NSBBs/carvedilol with LSM >25 kPa should continue treatment without need for endoscopy 1

Common Pitfalls to Avoid

• Do not discontinue beta-blockers prematurely: Only consider stopping if CSPH has resolved (LSM <12 kPa, platelets >150 G/L) 1
• Do not restrict protein intake: This outdated practice worsens sarcopenia and does not prevent hepatic encephalopathy 1, 6
• Do not use metformin if GFR <30 mL/min: Risk of lactic acidosis increases significantly 1
• Do not rely on conventional coagulation tests (PT/INR) to assess bleeding risk; these do not reflect true hemostatic status in cirrhosis 7